Integrated Genomic Analysis of Breast Cancers

1. Solinas-Toldo S, Lampel S, Stilgenbauer S, et al. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances.Genes Chromosomes Cancer. 1997; 20(4): 399-407.10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-ISearch in Google Scholar

2. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998; 20(2): 207-211.10.1038/2524Search in Google Scholar

3. van Beers EH, Nederlof PM. Array-CGH and breast cancer. Breast Cancer Res. 2006; 8(3): 210-219.10.1186/bcr1510Search in Google Scholar

4. Curtis C, Lynch AG, Dunning MJ, et al. The pitfalls of platform comparison: DNA copy number array technologies assessed. BMC Genomics. 2009; 10: 588-610.10.1186/1471-2164-10-588Search in Google Scholar

5. Bertucci F, Houlgatte R, Nguyen C, Viens P, Jordan BR, Birnbaum D. Gene expression profiling of cancer by use of DNA arrays: how far from the clinic? Lancet Oncol. 2001; 2(11): 674-682.10.1016/S1470-2045(01)00557-5Search in Google Scholar

6. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406 (6797): 747-752.10.1038/35021093Search in Google Scholar

7. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98(19): 10869-10874.10.1073/pnas.191367098Search in Google Scholar

8. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009; 360(8): 790-800.10.1056/NEJMra0801289Search in Google Scholar

9. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003; 362(9381):362-369.10.1016/S0140-6736(03)14023-8Search in Google Scholar

10. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004; 22(12): 2284-2293.10.1200/JCO.2004.05.166Search in Google Scholar

11. Bonnefoi H, Potti A, Delorenzi M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 2007; 8(12): 1071-1078.10.1016/S1470-2045(07)70345-5Search in Google Scholar

12. Farmer P, Bonnefoi H, Anderle P, et al. A stromarelated gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009; 5(1): 68-74.10.1038/nm.1908Search in Google Scholar

13. Dunn L, Demichele A. Genomic predictors of outcome and treatment response in breast cancer. Diagn Mol Ther. 2009; 13(2): 73-90.10.1007/BF03256317Search in Google Scholar

14. Gelsi-Boyer V, Trouplin V, Adélaïde J, et al. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer. 2008; 8: 299-313.10.1186/1471-2407-8-299Search in Google Scholar

15. Bergamaschi A, Kim YH, Wang P, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer. 2006; 45(11): 1033-1040.10.1002/gcc.20366Search in Google Scholar

16. Chin K, de Vries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006; 10(6): 529-541.10.1016/j.ccr.2006.10.009Search in Google Scholar

17. Stransky N, Vallot C, Reyal F, et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet. 2006; 38(12): 1386-1396.10.1038/ng1923Search in Google Scholar

18. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10(6): 515-527.10.1016/j.ccr.2006.10.008Search in Google Scholar

19. Adélaïde J, Finetti P, Bekhouche I, et al. Integrated profiling of basal and luminal breast cancers. Cancer Res. 2007; 67(24): 11565-11575.10.1158/0008-5472.CAN-07-2536Search in Google Scholar

20. Chin SF, Teschendorff AE, Marioni JC, et al. Highresolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol. 2007; 8(10): R215-R231.10.1186/gb-2007-8-10-r215Search in Google Scholar

21. Bernard-Pierrot I, Gruel N, Stransky N, et al. Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res. 2008; 68(17): 7165-7175.10.1158/0008-5472.CAN-08-1360Search in Google Scholar

22. Vincent-Salomon A, Lucchesi C, Gruel N, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res. 2008; 14(7): 1956-1965.10.1158/1078-0432.CCR-07-1465Search in Google Scholar

23. André F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009; 15(2): 441-451.10.1158/1078-0432.CCR-08-1791Search in Google Scholar

24. Horlings HM, Lai C, Nuyten DS, et al. Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients. Clin Cancer Res. 2010; 16(2): 651-663.10.1158/1078-0432.CCR-09-0709Search in Google Scholar

25. Popovici C, Basset C, Bertucci F, et al. Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene. Genes Chromosomes Cancer. 2002; 35(3): 204-218.10.1002/gcc.10107Search in Google Scholar

26. Adélaïde J, Huang HE, Murati A, et al. A recurrent chromosome translocation breakpoint in breast and pancreatic cancer targets the heregulin/NRG1 gene at 8p12. Genes Chromosomes Cancer. 2003; 37(4): 333-345.10.1002/gcc.10218Search in Google Scholar

27. Huang HE, Chin S-F, Ginestier C, et al. A recurrent chromosome breakpoint in breast cancer at the NRG1/ neuregulin 1/heregulin gene. Cancer Res. 2004; 64(19): 6840-6844.10.1158/0008-5472.CAN-04-1762Search in Google Scholar

28. Letessier A, Ginestier C, Charafe-Jauffret E, et al. ETV6 gene rearrangements in invasive breast carcinoma. Genes Chromosomes Cancer. 2005; 44(1): 103-108.10.1002/gcc.20200Search in Google Scholar

29. Letessier A, Garrido-Urbani S, Ginestier C, et al. Correlated break at PARK2/FRA6E and loss of AF- 6/ Afadin protein expression are associated with poor outcome in breast cancer. Oncogene. 2007; 26(2): 298-307.10.1038/sj.onc.1209772Search in Google Scholar

30. Ginestier C, Bardou V-J, Popovici C, et al. Absence of FHIT protein expression correlates with adverse evolution in good prognosis localized breast cancer. Int J Cancer. 2003; 107(5): 854-862.10.1002/ijc.11462Search in Google Scholar

31. Letessier A, Sircoulomb F, Ginestier C, et al. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer. 2006; 6(1): 245-257.10.1186/1471-2407-6-245Search in Google Scholar

32. Bekhouche I, Finetti P, Adélaïde J, et al. Genome profiling of inflammatory breast cancer. PLoS One. 2011; 6(2): e16950-16962.10.1371/journal.pone.0016950Search in Google Scholar

33. Sircoulomb F, Bekhouche I, Finetti P, et al. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer. 2010; 10: 539-556.10.1186/1471-2407-10-539Search in Google Scholar

34. Addou-Klouche L, Adélaïde J, Finetti P, et al. Loss, mutation and deregulation of L3MBTL4 in breast cancers. Mol Cancer. 2010; 9(1): 213-225.10.1186/1476-4598-9-213Search in Google Scholar

35. Sircoulomb F, Nicolas N, Ferrari A, et al. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med. 2011; 3(3): 153-166.10.1002/emmm.201100121Search in Google Scholar

36. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6): 415-428.10.1038/nrg816Search in Google Scholar

37. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev. 2004; 18(19): 2315-2335.10.1101/gad.1232504Search in Google Scholar

38. Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene. 2007; 26(47): 6697-6714.10.1038/sj.onc.1210755Search in Google Scholar

39. Goll MG, Bestor TH. Histone modification and replacement in chromatin activation. Genes Dev. 2002; 16(14): 1739-1742.10.1101/gad.1013902Search in Google Scholar

40. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006; 31(2): 89-97.10.1016/j.tibs.2005.12.008Search in Google Scholar

41. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007; 16(Spec 1): R50-R59.10.1093/hmg/ddm018Search in Google Scholar

42. Wildschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene. 2002; 21(35): 5462-5482.10.1038/sj.onc.1205606Search in Google Scholar

43. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: The time is now. Crit Rev Oncol Hematol. 2008; 68(1): 1-11.10.1016/j.critrevonc.2008.03.001Search in Google Scholar

44. Ordway JM, Budiman MA, Korshunova Y, et al. Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One. 2007; 2(12): e1314-1325.10.1371/journal.pone.0001314Search in Google Scholar

45. Bediaga NG, Acha-Sagredo A, Guerra I, et al. DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res. 2010; 12(5): R77-R78.10.1186/bcr2721Search in Google Scholar

46. Holm K, Hegardt C, Staaf J, et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 2010; 12 (3): R36-R51.10.1186/bcr2590Search in Google Scholar

47. van der Auwera I, Yu W, Suo L, et al. Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One. 2010; 5(9): e12616-12625.10.1371/journal.pone.0012616Search in Google Scholar

48. Fackler MJ, Umbricht CB, Williams D, et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res. 2011; 71(19): 6195-6207.10.1158/0008-5472.CAN-11-1630Search in Google Scholar

49. Hill VK, Ricketts C, Bieche I, et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 2011; 71(8): 2988-2999. 10.1158/0008-5472.CAN-10-4026Search in Google Scholar